Benoît You
Université Claude Bernard Lyon 1(FR)Lyon College(US)Hospices Civils de Lyon(FR)Hospices Civils de Lyon(FR)Mersen (France)(FR)Honghu People’s Hospital(CN)Wuhan Business University(CN)Hôpital Lyon Sud(FR)Centre de Recherche en Nutrition Humaine Rhône-Alpes(FR)Centre de Recherche en Cancérologie de Lyon(FR)Arcagy Gineco(FR)Eau de Paris (France)(FR)University College London(GB)Fuzhou University(CN)HCL Technologies (India)(IN)
Publications by Year
Research Areas
Ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, Intraperitoneal and Appendiceal Malignancies, BRCA gene mutations in cancer, Cancer Genomics and Diagnostics
Most-Cited Works
- → Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer(2019)1,962 cited
- → Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial(2017)1,678 cited
- → Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study(2020)443 cited
- → Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial(2023)311 cited
- → A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors(2019)242 cited
- → The official French guidelines to protect patients with cancer against SARS-CoV-2 infection(2020)188 cited